Lomitapide provided a significant, clinically meaningful LDL cholesterol reduction and has the potential to be an efficient, LDL receptor-independent option for paediatric patients with HoFH.
The Best of ObesityWeek® | Your selection of highlights and key takeaways from ObesityWeek®.
Daniel Drucker, MD, recent winner of our Lifetime Achievement Laureate Award, the top honors in the field, shares his story as one of the first…
The Best of ObesityWeek® | Your selection of highlights and key takeaways from ObesityWeek®.
Attend one of our new Member Orientation and Networking sessions to gain insight on how to make the most of your membership and connect with…
Previous research showed a limited effect of weight-loss surgery in people with T2D. Is this still the case, and what might be driving that? Find…
The Endocrine Society works to reduce the prevalence of obesity, identify policy options to address obesity, and advocate for access to affordable care.
Please email advocacy@endocrine.org with any questions or for additional information.
Nature Reviews Endocrinology – Intricacies and obscurities of non-shivering thermogenesis
The Endocrine Society’s AI in Healthcare Vir tual Summit, November 8-9, 2024, is an innovative 2-day virtual event designed to inform providers, healthcare professionals, researchers,…
Our awards program supports your dedication to excellence in research, education, and clinical practice in endocrinology. View our open award opportunities and apply today or…
